Zai Lab Ltd (HK:9688) has released an update.
Zai Lab Limited, a biopharmaceutical company, awarded share options and restricted share units to certain employees under its 2022 Equity Incentive Plan. On June 3, 2024, one employee was granted options to subscribe for 2,200 ADSs, and two employees were awarded a total of 3,600 restricted share units. The options have a ten-year validity and will vest annually over four years, provided the grantees remain employed with the company.
For further insights into HK:9688 stock, check out TipRanks’ Stock Analysis page.
